Second haploidentical stem cell transplantation for graft failure

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the safety and efficacy of a second haploidentical stem cell transplantation for patients who have experienced graft failure after their first transplant. The approach involves using a different donor and conditioning with fludarabine and cyclophosphamide. The trial aims to validate previous encouraging outcomes observed in a small, single-center study by expanding to a multicenter setting. Eligible participants include those with hematological malignancies who meet specific criteria related to their condition and timing of the second transplant.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* 1\. Primary disease: hematological malignancies (AML, CML, MDS, lymphoma, etc.); 2. Graft failure after the first haploidentical stem cell transplantation; 3. Time from the first transplantation to the second transplantation is less than 180 days; 4. Age≥14 years.

Exclusion Criteria:

* 1\. Active infections; 2. Active GVHD; 3. Organ dysfunction: hepatic injury (Tbil≥2ULN), renal injury (Cr≥1.5ULN), heart injury (EF%\<50% or symptomatic heart failure); 4. Eastern Cooperative Oncology Group (ECOG) score\>2; 5. Expected life time\<30 days; 5. Patients could not cooperate; 6. Other situations that are considered inappropriate for enrollment by the investigators,

Where it's running

• Peking University People's Hospital
  Beijing, Beijing Municipality, China Recruiting

Study contacts

• Principal investigator: Xiao-Jun Huang, M.D. — Institute of Hematology, Peking University People's Hospital
• Study coordinator: Yu-qian Sun, M.D.
• Email: sunyuqian83@hotmail.com
• Phone: +86-10-88324577

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Modified second transplantation for patients with graft failure

  This study is testing a new approach to a second stem cell transplant for patients who didn't fully recover after their first transplant to see if it helps them get better, especially with their platelet counts.

  Recruiting Peking University People's Hospital · Beijing, Beijing Municipality · NCT06512545

• Differences in Outcomes After Allograft vs Autograft in Revision ACL Repair

  This study looks at whether using donor tissue (allograft) versus the patient’s own tissue (autograft) in revision ACL surgery leads to different results.

  Recruiting Istituto Ortopedico Rizzoli · Bologna, Bologna · NCT07671235

• Combining ruxolitinib with corticosteroids for severe acute graft‑versus‑host disease

  This trial tests whether adding ruxolitinib to corticosteroids as first‑line treatment helps people who develop severe acute graft‑versus‑host disease after a first stem cell transplant.

  Recruiting Phase 2 Chinese PLA General Hospital · Beijing · NCT07509749

• Venetoclax added to reduced-intensity conditioning for combined stem cell and kidney transplant

  This trial tests whether adding venetoclax to a reduced-intensity conditioning regimen is safe for adults with blood cancers who are receiving a combined stem cell and kidney transplant from a matched or partially matched donor.

  Recruiting Early Phase 1 Massachusetts General Hospital · Boston, Massachusetts · NCT07358195

• First-line ruxolitinib plus corticosteroids for grade II acute graft-versus-host disease

  This trial will test whether adding ruxolitinib to standard corticosteroids helps people with new grade II acute graft-versus-host disease after an allogeneic stem cell transplant.

  Recruiting Phase 2 Chinese PLA General Hospital · Beijing, Beijing Municipality · NCT07340723

• Ruxolitinib-enhanced haploidentical transplant for children and young adults with sickle cell disease

  This trial will test whether adding ruxolitinib to a reduced-intensity haploidentical transplant lowers the risk of graft failure in children and young adults with sickle cell disease.

  Recruiting Phase 1/2 Arkansas Children's Hospital Research Institute · Aurora, Colorado and 3 other locations · NCT07252050

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.